Janux Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-0.55 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | – | $-0.38 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | During market hours | – | – | – |
Press releases
Announcements Janux Therapeutics filed with the SEC
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Announces Proposed Public Offering
Other events · EX-99.1 to Form 8-K
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and
Other events · EX-99.2 to Form 8-K
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Creating Transformative Medicines to Improve Patients’ Lives Program Updates December 2, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Other events · EX-99.2 to Form 8-K
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
Tumor Activated Cancer Therapeutics Restoring anti-tumor immune responses to treat cancer patients February 26, 2024 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Program Updates July 2023 Exhibit
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K